Nemolizumab - Uses, Dosage, Precautions, Side Effects, and Pharmacological Aspects

Overview

On the 13th of August, the United States Food and Drug Administration approved Nemolizumab (Nemolizumab-ilto), a humanized anti-human IL(interleukin)-31 receptor. A monoclonal antibody is indicated for prurigo nodularis. Prurigo nodularis is a skin condition that is characterized by very itchy papules. This product offers an innovative approach to selectively target the IL-31 receptor to manage inflammation and severe pruritus related to prurigo nodularis. This article primarily discusses the mechanism, efficacy, and clinical application of Nemolizumab-ilto, particularly how this agent could significantly impact patient outcomes.

Drug Group

Nemolizumab belongs to the group of monoclonal antibody drugs, more specifically to an interleukin-31 receptor alpha antagonist. These are tailor-made antibodies. Thus, they interfere with the activity of either particular proteins or cells responsible for a specific disease process. This means, in this case, that Nemolizumab interferes with and inhibits IL-31 receptor activity to reduce inflammation and pruritus (skin itching).

Indications

Nemolizumab-ilto is prescribed for the treatment of prurigo nodularis in adults.

Dosage Forms and Available Strengths

Injection: A single-dose prefilled dual-chamber pen containing 30 mg (milligrams) of Nemolizumab-ilto as a white lyophilized powder in one chamber and water for injection in the other chamber.

For Patients

What Is Prurigo Nodularis?

Prurigo nodularis is a condition of the skin characterized by the development of nodules or bumps on the skin with a fine, intense itch. These nodules usually appear as firm, raised lesions on the arms, legs, and trunk. The itching can range from being very bad and constant to scratching, which further irritates the condition and might even cause damage to the skin. While the exact cause for the condition is not fully understood, it often resides with other conditions like eczema (inflammatory skin condition), chronic kidney disease, or even liver disease. Treatment thus involves symptomatic relief and managing underlying diseases that could precipitate the itch.

How Does the Nemolizumab Work?

Nemolizumab has been designed to bind and inhibit the interleukin-31 receptor alpha (IL-31RA). IL-31 is a cytokine involved in different inflammatory processes: itchiness, inflammation, and skin changes. By blocking the IL-31RA, Nemolizumab reduces the actions of IL-31 and reduces symptoms related to these conditions, including itching and inflammation.

How Is Nemolizumab Administered?

• Nemolizumab-ilto is injected under the skin (subcutaneously).

• A healthcare provider should train patients or caregivers to prepare and inject Nemolizumab-ilto. After training, patients can self-inject themselves.

• For the initial dose, each injection is given at a different site. Inject into the upper thighs or abdomen (avoid the area around the navel). The upper arm should be used only by a caregiver or healthcare provider.

• Alternate injection sites and avoid tender, inflamed, swollen, or damaged areas.

• Please refer to the provided instructions for detailed guidance on usage.

Preparation for Use

• Let Nemolizumab-ilto reach room temperature (30 to 45 minutes) before use.

• Check the powder and diluent for changes in color or particles. Only use them if they are as described.

• Reconstitute Nemolizumab-ilto before use. The solution should be clear to slightly yellow. Do not use it if it is discolored or has particles.

• Use the reconstituted Nemolizumab-ilto within four hours and discard any unused portions afterward.

• Refer to the instructions for detailed preparation steps.

What Are the Side Effects of Nemolizumab?

Allergic reactions (hypersensitivity) may occur with Nemolizumab; some can be serious.

If any of the following symptoms appear, stop using Nemolizumab and seek immediate medical help:

• Breathing difficulties or wheezing.

• Swelling of the face, lips, mouth, tongue, or throat.

• Fainting, dizziness, or lightheadedness.

• Fast pulse.

• Swollen lymph nodes.

• Joint pain.

• Fever.

• Skin rash (red or rough).

• Nausea or vomiting.

• The general feeling of illness.

• Abdominal cramps.

Common side effects of Nemolizumab include:

• Headache.

• Skin rashes.

What Are the Things to Inform the Doctor Before Taking Nemolizumab?

Before starting Nemolizumab, inform the healthcare provider about all medical conditions, including if:

• Inform about the schedule for any vaccinations. Live vaccines should be avoided before or during Nemolizumab treatment.

• Pregnant, planning to become pregnant, or breastfeeding. The effects of Nemolizumab on an unborn baby or in breast milk are unknown.

• Taking any medications, including prescriptions, over-the-counter drugs, vitamins, and herbal supplements.

Dietary Considerations

None.

Missed Dose

If a dose is missed, inject it as soon as possible, then resume the regular dosing schedule with the next dose at the planned time.

Overdose

In case of overdosage, contact poison control for updated recommendations. Observe the patient for any symptoms of adverse reactions and provide appropriate symptomatic treatment promptly.

Storage and Handling

Refrigerate the pen at 36 to 46 degrees Fahrenheit (two to eight degrees Celsius) in the original carton, protected from light. Do not freeze or expose to heat. The pen can be kept at room temperature (up to 77 degrees Fahrenheit or 25 degrees Celsius) for up to 90 days. Use it before the expiration date or 90 days after removal from the refrigerator, whichever comes first.

Disposal:

Unused medicine or waste from the vaccine is discarded safely by the healthcare authorities according to the local or garbage disposal guidelines, or it can also be discarded as per FDA guidelines and protocols for safe drug disposal.

For Doctors

Description:

Nemolizumab-ilto is an interleukin-31 receptor alpha (IL-31RA) antagonist. It is a humanized monoclonal IgG or immunoglobulin G antibody with a molecular weight of approximately 144 kDa (kilo Dalton). The product is produced using recombinant DNA or deoxyribonucleic acid technology in Chinese Hamster Ovary cells. Each pen delivers 30 mg/0.49 mL (milligrams per milliliter) after reconstitution.

The carton contains one pen.

Pack Size: one prefilled pen.

Active Ingredient: 30 mg of Nemolizumab-ilto.

Inactive Ingredients:

• Arginine hydrochloride: 9.5 mg.

• Poloxamer: 188: 0.15 mg.

• Sucrose: 25.8 mg.

• Trometamol: 0.10 mg.

• Tris hydrochloride (for pH or potential of Hydrogen adjustment).

Diluent: Water for injection (in the other chamber).

Reconstitution and Administration: After reconstitution, each prefilled pen delivers 30 mg of Nemolizumab-ilto in 0.49 mL with a pH of 6.7 to 7.3.

Warnings and Precautions

• Hypersensitivity: Hypersensitivity reactions, such as facial angioedema, have been reported with Nemolizumab-ilto. It is contraindicated in patients with known hypersensitivity to Nemolizumab-ilto or excipients. If a significant hypersensitivity reaction occurs, promptly administer appropriate treatment and discontinue Nemolizumab-ilto.

• Vaccinations: Complete all recommended age-appropriate vaccinations before starting Nemolizumab-ilto. Avoid live vaccines during treatment with Nemolizumab-ilto, as it is unknown if they may affect the safety or effectiveness of the vaccines. There is no data on responses to non-live vaccines during Nemolizumab-ilto treatment.

What Are the Pharmacological Actions of Nemolizumab?

Mechanism of Action: Nemolizumab-ilto is a humanized IgG2 or immunoglobulin G monoclonal antibody that selectively binds to IL-31 receptor alpha (IL-31 RA), inhibiting IL-31 signaling. IL-31 is a cytokine involved in pruritus, inflammation, epidermal dysregulation, and fibrosis. Nemolizumab-ilto blocks IL-31-induced responses, including the release of proinflammatory cytokines and chemokines.

Pharmacokinetics

After a single subcutaneous dose of Nemolizumab-ilto, exposure increases proportionally between 0.03 and three mg/kg (milligrams per kilogram). With multiple doses, exposure remains dose-proportional up to 30 mg but decreases by nine percent at 60 mg and 15 percent at 90 mg.

In patients with prurigo nodularis, steady-state concentrations are 3.04 µg/mL (micrograms per milliliter) for those under 198 pounds and 3.66 µg/mL for those 198 pounds or more, achieved by week four and week 12, respectively.

After a 60 mg dose, peak concentrations of 7.5 µg/mL occur around six days after the dose. The drug’s volume of distribution is 7.67 L (liters). It has a terminal half-life of about 19 days and a clearance rate of 0.263 L/day (liters per day). It is expected to be broken down into small peptides like endogenous IgG.

Specific Populations:

• Geriatric: No significant differences in pharmacokinetics based on age. No dose adjustment is needed.

• Renal or Hepatic Impairment: No significant differences with mild to moderate impairments. The effects of severe impairments are unknown.

• Body Weight: Exposure decreases with increasing body weight. Steady-state exposure is about 1.7 times lower in those over 191 pounds than those under 136 pounds. This affects skin lesion efficacy but not pruritus improvement.

Immunogenicity

• The incidence of anti-drug antibodies (ADAs) varies based on the sensitivity and specificity of the assay used. As different assay methods prevent meaningful comparisons of ADA incidence across studies, comparisons with other studies, including those on Nemolizumab-ilto or other Nemolizumab products, are not feasible.

• In phase 3 trials (OLYMPIA 1 and OLYMPIA 2) lasting up to 24 weeks, seven percent of subjects developed treatment-emergent ADAs, and three percent developed neutralizing antibodies.

• No clinically significant effects of anti-drug antibodies on the pharmacokinetics, safety, or efficacy of Nemolizumab-ilto were observed during the 24-week treatment period.

Non-Clinical Toxicity:

No animal studies have been done to assess the cancer-causing or genetic mutation risks of Nemolizumab-ilto. In sexually mature cynomolgus monkeys given Nemolizumab-ilto subcutaneously at doses up to 25 mg/kg every two weeks for six months, no changes in fertility-related factors like reproductive organ structure, menstrual cycle length, or sperm/testicular analysis were observed. However, these animals were not tested for mating fertility.

What Are the Contraindications of Nemolizumab?

Nemolizumab-ilto should not be used in patients with known hypersensitivity to Nemolizumab-ilto or any of its excipients.

What Are the Drug Interactions of Nemolizumab?

Cytochrome P450 Substrates

• Chronic inflammation can increase specific cytokines (for example, IL or interleukin-1, IL-6, IL-10, TNFα, or tumor necrosis factor-alpha, IFN, or interferon-gamma), which may alter the formation of CYP450 enzymes. Nemolizumab-ilto may affect serum cytokine levels and influence CYP450 enzyme activity.

• When starting or stopping Nemolizumab-ilto in patients taking CYP450 substrates, especially those with a narrow therapeutic index (e.g., Warfarin or Cyclosporine), consider monitoring the drug's effect or concentration and adjusting the dosage if necessary.

Clinical Studies

Two randomized, double-blind, placebo-controlled trials (OLYMPIA 1 and OLYMPIA 2) with 560 adults assessed Nemolizumab-ilto for prurigo nodularis. Participants had severe itching and at least 20 nodular lesions. Dosing varied by weight: 60 mg initially, then 30 or 60 mg every four weeks. At 16 weeks, Nemolizumab-ilto significantly improved skin lesions and itching compared to the placebo. In OLYMPIA 1, 22 percent of Nemolizumab-ilto patients saw a notable improvement, versus two percent on placebo; in OLYMPIA 2, 25 percent of Nemolizumab-ilto patients showed improvement compared to four percent on placebo. Nemolizumab-ilto also significantly reduced itching intensity and achieved better results in IGA or Investigator's Global Assessment scores, compared to placebo. No significant response differences were found based on weight, age, gender, race, history of atopy, or prior treatment.

Use in Specific Populations

• Pregnancy: Data on Nemolizumab-ilto in pregnant women are limited, so risks for birth defects or miscarriage are not fully known. Nemolizumab-ilto can cross the placenta, and animal studies show potential risks at high doses, though their relevance to humans is unclear. The general risk of birth defects and miscarriage is two to four percent and 15 to 20 percent, respectively.

• Clinical Considerations: Nemolizumab-ilto may affect the immune response, so live vaccines should be delayed in infants exposed in utero, ideally for at least three months.

• Lactation: No data is available regarding the presence of Nemolizumab-ilto in human milk or its effects on breastfed infants. It was found in monkey milk, but this does not predict human milk levels. Consider the benefits of breastfeeding against potential risks from Nemolizumab-ilto or the mother's condition.

• Pediatric Use: The safety and effectiveness of children still need to be established.

• Geriatric Use: Nemolizumab-ilto has been used in older adults, but there is insufficient data to determine if they respond differently than younger adults.